Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.39 USD
-0.46 (-3.88%)
Updated May 24, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVAX 11.39 -0.46(-3.88%)
Will DVAX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
Other News for DVAX
Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced Right? A Comprehensive Guide
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Hold Rating on Dynavax Amidst FDA Setback and Long-term Profitability Focus
Analysts’ Top Healthcare Picks: aTyr Pharma (LIFE), Dynavax (DVAX)